Chiral Plasmons in Protein-Nanoparticle Hybrid Materials for Application as Biosensors

Project Information

CINMAB

Grant agreement ID: 708321

DOI

10.3030/708321

Project closed

EC signature date 24 February 2016

Start date 20 October 2016

End date 19 October 2018

Funded under

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Total cost

€ 170 121,60

EU contribution

€ 170 121,60

Coordinated by

ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE
Spain

Periodic Reporting for period 1 - CINMAB (Chiral Plasmons in Protein-Nanoparticle Hybrid Materials for Application as Biosensors)

Reporting period: 2016-10-20 to 2018-10-19

Summary of the context and overall objectives of the project

Problem being addressed: Early diagnosis and therapy of neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) is a major challenge for the scientific community. While the mechanisms leading to these class of diseases is not fully understood, a common hallmark is a conformational change of native proteins leading to the aggregation and formation of insoluble amyloid fibrils. Various difficulties associated with the detection of protein aggregates, including (i) the insoluble nature of aggregates, (ii) differences in conformational and misfolding patterns depending on the type of protein, and (iii) the diverse nature of aggregates, ranging from 2D crystals to amorphous structures and fibrils making the problem a challenging one. Plasmonic nanoparticles (NPs) have recently attracted large attention in the biomedical field. Hence, the major aim of the project was to develop a new diagnostic platform for the detection of neurodegenerative diseases using plasmonic NPs.

Impact on society: Untreatable conditions arising from age-related neurodegenerative diseases are matter of huge concern. The increasing socioeconomic impact of these diseases has boosted research interests on the fundamental aspects of these disorders. The early diagnosis as well as treatment of these diseases is of prime importance in tackling these social challenges. Currently, almost 16% of the European population is over the age of 65 years, and this figure is expected to reach 25% by 2030. Over 6.3 million people around the world are affected by PD and related disorders among which 1.2 million are in Europe. Approximately €130 billion per annum is spent on people with dementia across Europe, highlighting the socioeconomic impact of such diseases. Therefore, these diseases are considered as one of the leading medical and societal challenges faced by the European society, demanding early diagnosis and therapy. Considering the relevance of this topic, the project was focused on the use of plasmonic NPs for the detection of amyloid fibrils in PD and prion diseases.

Overall objective: The major objective of the project was to develop a plasmonic platform for the detection of neurodegenerative diseases. The identification of protein fibrils, which are the hallmark of these diseases, is pivotal in disease diagnosis and development of therapeutic strategies. Our objective was to develop a methodology for the specific detection of amyloid fibrils using chiral effects in plasmonic NPs. The formation of amyloid fibrils based on α-synuclein (aggregation of which causes PD) was probed using gold nanorods (Au NRs). Au NRs showed no apparent interaction with monomeric proteins but effective adsorption onto fibril structures via noncovalent interactions. The technique was successfully applied for the detection of fibrils in PD-affected human brain samples.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

Detection of amyloid fibrils in Parkinson’s disease (recombinant proteins)
The main objective of the project was to differentiate the stable monomeric state of the protein from its aggregated fibrillar state using Au NRs as substrates (Scheme 1). Initial investigations were carried out on recombinant α-synuclein. To separate solutions of Au NRs, α-synuclein monomers as well as aggregates were added. No Extinction and CD spectral changes were observed even after addition of higher concentration (1µM) of protein monomers (inset, Fig. 1a,b) indicating a weak protein–NR interaction. In contrast, a gradual red-shift and broadening of the localized surface plasmon resonance (LSPR) along with a bisignate circular dichroism (CD) signal at the LSPR was observed in presence of protein fibrils. The CD signal exhibited a time-dependent red-shift in the peak position accompanied by an increase in intensity (Fig. 1a,b). The red-shift in extinction indicates preferential tip-to-tip assembly of NRs whereas the CD signals at the LSPR is indicative of a 3D chiral arrangement of the Au NRs directed by helical structure of the template.
Better insight into the nature of assembly was obtained through transmission electron microscopic (TEM) imaging of the nanocomposites. While the TEM images of protein monomer-Au NRs mixture showed no specific patterns (Fig. 2a), solutions containing protein fibrils exhibited hybrid structures with NRs arranged following the direction of the fibrils (Fig. 2b). Cryogenic EM tomography experiments accomplished a clear double-helical structure for the NR assembly (Fig. 2c). High positive (+30 mV) and negative (-30 mV) zeta potential values observed for NRs and fibrils, respectively suggested the NR-protein fibril interactions to be likely electrostatic. Theoretical modelling results were in good agreement with the experimental data establishing that the observed optical activity arises from dipolar coupling between adjacent NRs. Intense chiroptical activity of Au NRs allowed the detection of amyloid fibrils down to nanomolar concentrations.

Detection of Parkinson’s disease in human brain homogenates
With an ultimate aim of developing a biodetection platform for potential applications, experiments were designed on brain homogenates to identify the presence of protein fibrils in human brain samples (samples collected postmortem). Brain samples collected from PD-affected patients were homogenized in a suitable buffer. Healthy brain homogenates were used as controls. Addition of purified brain samples to Au NRs resulted in a red-shift in the longitudinal LSPR in the case of PD-affected samples but least effect from healthy controls (Fig. 3a). Interestingly, intense bisignate CD signals were recorded from the PD sample. However, experiments with purified healthy controls showed only weak CD signals exhibiting a clear distinction between PD-affected samples and healthy controls (Fig. 3b).

Extension of the technique for the detection of infectious prion fibrils
To establish a wider applicability of the proposed technique, investigations on infectious prion protein from bank vole was carried out. Addition of monomeric PrP to Au NRs showed no spectral changes ruling out any protein interaction with Au NRs. In contrast, addition of prion fibrils resulted in the red-shift and broadening of the Au NR longitudinal plasmon band indicating tip to tip assembly of NRs (Fig. 4a). Intense CD signals with a negative couplet at the LSPR indicated the helical assembly of NRs on the fibril surface (Fig. 4b). These experiments established a new technique for the detection of infectious prion fibrils.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Neurodegenerative disease such as AD, PD and prion diseases are matter of huge concern in European society. A large sum of money is spend every year on the treatment of people with dementia across Europe, highlighting the medical and societal impact of these diseases. Early detection and therapy of such diseases is hence challenging and matter of prime importance for researches working in this field. Considering the relevance of the problem, our research was focused on developing a sensing platform for the detection of this class of diseases. While plasmonic NPs have emerged as potential candidates in biosensing and hyperthermia, there have been no attempts in utilizing their specific properties in the detection of neurodegenerative diseases. We used plasmonic chirality, a highly sensitive technique, for the detection of fibrils at nanomolar concentrations.

Detection of Parkinson’s disease in in human brain samples. (a) Extinction and (b) circular dichrois

Detection of prion fibrils. (a) Extinction and (b) circular dichroism spectra of gold nanorods monit

TEM images of nanocomposites. (a, b) TEM images of gold nanorods in the presence of α-synuclein mono

Detection of amyloid fibrils. (a, b) Time dependent extinction (a) and circular dichroism (b) spectr

Scheme illustrating the differential interaction of synuclein monomers and fibrils with gold nanorod

Breaking of nanofibrils using the hyperthermia effect of gold nanorods. (a-c) TEM images of gold nan